IP Library Granted Patent US 9,181,298
Granted Patent B2
US 9,181,298 · App. 12/273,638 · Granted Nov 10, 2015

Intermediates for macrocyclic compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,298
App. No.
12/273,638
Granted
Nov 10, 2015
Kind
B2
Abstract

The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n 1 , m, p Z 1 , Z 2 , and Z 3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Claims (18)

1. A compound of formula W-T-Y, wherein W and Y are independently selected from the group consisting of —OH, —NH 2 and —NHR 60 , wherein R 60 is lower alkyl, and T is the following structure:

wherein

L 5 is CH or N;

L 6 is CR 52 R 53 or O, wherein R 52 and R 53 are independently selected from the group consisting of hydrogen and lower alkyl;

R 54 and R 55 are independently lower alkyl; and, when L 6 is CR 52 R 53 , R 55 is also selected from hydroxy;

R 56 is hydrogen or lower alkyl, and R 57 is selected from the group consisting of hydrogen and lower alkyl, and, when no double bond is present between the carbon atoms to which R 56 and R 57 are bonded, R 56 and R 57 are also independently selected from hydroxy; and

(W) indicates the point of attachment of T to W; and (Y) indicates the point of attachment of T to Y;

with the proviso that T is not the following:

further comprising one or more protecting groups.

2. A compound of formula W-T-Y, wherein W and Y are independently selected from the group consisting of —OH, —NH 2 and —NHR 60 , wherein R 60 is lower alkyl, and T is the following structure:

wherein

L 5 is CH or N;

L 6 is CR 52 R 53 or O, wherein R 52 and R 53 are independently selected from the group consisting of hydrogen and lower alkyl;

R 54 and R 55 is lower alkyl; and, when L 6 is CR 52 R 53 , R 55 is also selected from hydroxy;

R 56 and R 57 are independently selected from the group consisting of hydrogen and lower alkyl, and, when no double bond is present between the carbon atoms to which R 56 and R 57 are bonded, R 56 and R 57 are also independently selected from hydroxy; and

(W) indicates the point of attachment of T to W; and (Y) indicates the point of attachment of T to Y;

with the proviso that T is not the following:

3. The compound of claim 2 , further comprising one or more protecting groups.

Assignments (2)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →